• First Patient Dosed in DSP-0509 Trial americanpharmaceuticalreview
    September 14, 2018
    Boston Biomedical has initiated clinical trial activities for DSP-0509, an investigational Toll-like receptor (TLR) 7 agonist. DSP-0509 is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain the immune-mediated antitu
PharmaSources Customer Service